Edurne Berra got her Degree in Pharmacy at the University of Navarra (Pamplona, Spain) and a Licence Spéciale in Toxicology at the ULB (Brussels, Belgium). She started her research career, supervised by Dr J. Moscat at the CBM “Severo Ochoa” (Madrid, Spain), studying the signalling pathways triggered by the atypical PKC isotypes (PKCζ and λ). After a first postdoctoral at the Glaxo-Wellcome-CSIC laboratory of Molecular and Cell Biology (Madrid, Spain), Edurne moved to Dr J. Pouysségur’s lab (Nice, France) where she was appointed Chargé de Recherche (CNRS-CR1) and she got her HDR (Habilitation à la Direction de Recherche). In November 2007, Edurne joined CIC bioGUNE to lead her independent group, which is devoted to establish new players of the hypoxia signalling pathway, and to further translate this research to potential therapeutic applications in hypoxia related pathologies such as cancer.
Edurne has authored more than 50 scientific publications in highly prestigious journals (Cell, EMBO Journal, PNAS...) that received more than 7000 citations. Edurne has been awarded the Fundación Renal “Iñigo Alvarez de Toledo” Prize (2007), the “Dr Joseph Amalrich” Prize for Excellence in Cancer Research (2002) and the HFSP (1999) and EMBO (1998) Fellowships. Edurne is member of the Spanish Society for Biochemistry and Molecular Biology (SEBBM), the Spanish Society for Cancer Research (ASEICA) and the European Association for Cancer Research (EACR), and she is on the committee of the Spanish and the European Hypoxia Network
Latest Publications
2021
2020
2019
2015
2014
2013
2012
2008
2007
The research in the Carracedo lab is aimed at deconstructing the essential requirements of cancer cells with special emphasis on the translation of the acquired knowledge from bench to bedside. In order to define the genuine features of cancer cells, we focus on the signalling and metabolic alterations in prostate and breast cancer. Through the use of a hierarchical approach with increasing complexity, we work on cell lines and primary cultures (using cell and molecular biology technologies), mouse models of prostate cancer that are faithful to the human disease and the analysis of human specimens through the development of prospective and retrospective studies. Our work stems from the hypothesis that cancer is driven by signalling and metabolic alterations that, once identified, can be targeted for therapy. The center and our collaborator institutions offer state-of-the-art technologies (from OMICS to in vivo imaging), which allow us to build and answer our hypotheses with high level of confidence.
To address our scientific questions in cancer, the Carracedo lab has developed a series of research lines:
- Bioinformatics-based discovery. The lab takes full advantage on publicly available human prostate and breast cancer datasets in order to identify candidate genes to contribute to cancer pathogenesis, progression and response to therapy. Best hits are then validated employing genetic mouse models, xenograft surrogate assays and the latest advances in cellular and molecular biology combined with OMICs technologies.
- Genetic mouse models as a source for the identification of novel cancer players. Genetically engineered mouse models (GEMMs) can faithfully recapitulate many aspects of human cancer. Dr. Carracedo envisions the molecular analysis of GEMMs with high throughput technologies as a mean to identify novel cancer-related genes. These hits are then validated through the analysis of human cancer specimens and cellular and molecular biology approaches.
- Multi-OMICs analysis for non-invasive biomarker identification. Biofluids are the perfect source for cancer biomarkers that can inform about the presence or features of cancer. The lab has undertaken a biomarker discovery approach by applying the latest OMICs technologies to biofluid specimens from well-annotated prostate cancer patients, in order to define better molecules that inform about this disease.
-
Principal Investigator
Arkaitz Carracedo
ERC Consolidator Grant - Ikerbasque Research Professor IKERBASQUE RESEARCH FELLOW -
Marco Piva
Ikerbasque Research Fellow -
Oihana Iriondo Martinez de Zuazo
Ikerbasque Research Fellow -
Isabel Mendizabal
Ikerbasque Research Fellow RESEARCH ASSISTANT -
Natalia Martín Martín
-
Amaia Zabala Letona
AECC Researcher POST DOCTORAL RESEARCHER -
Amaia Ercilla Eguiarte
Juan de la Cierva Fellow -
Laura Camacho
-
Laura Bozal Basterra
AECC Postdoctoral Fellow TECHNICIANS / DOCTORAL CANDIDATES -
Maria Camila Salazar Palacio
-
Onintza Carlevaris
-
Encarnación Pérez Andrés
-
Saioa García Longarte
-
Kathrin Keim
-
Jon Corres Mendizabal
-
Mikel Pujana Vaquerizo
-
Sonia Fernández Ruiz
-
Mikel Arana Castañares
-
Ruben Amián Ruiz
-
Alice Macchia
-
Pablo Salvador Valera Sapena
-
Cristina Viera Bardon
-
Ivana Rondon Lorefice
MSCA-ITN Fellow -
Adrián Vicente Barrueco
-
Ianire Astobiza
-
Maider Fagoaga Eugui
-
Jana Crespo Trives
Members
Latest Publications
Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer
Martin-Morales, L;Manzano, S;Rodrigo-Faus, M;Vicente-Barrueco, A;Lorca, V;Nunez-Moreno, G;Bragado, P;Porras, A;Caldes, T;Garre, P;Gutierrez-Uzquiza, A
INTERNATIONAL JOURNAL OF CANCER
2022-10-03
CiberAMP: An R Package to Identify Differential mRNA Expression Linked to Somatic Copy Number Variations in Cancer Datasets
Caloto, R;Lorenzo-Martin, LF;Quesada, V;Carracedo, A;Bustelo, XR
BIOLOGY-BASEL
2022-10-01
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma
Davidson, SM;Schmidt, DR;Heyman, JE;'Brien, JPO;Liu, AC;Israelsen, WJ;Dayton, TL;Sehgal, R;Bronson, RT;Freinkman, E;Mak, HH;Fanelli, GN;Malstrom, S;Bellinger, G;Carracedo, A;Pandolfi, PP;Courtney, ...
CANCER RESEARCH
2022-07-01
Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
Arruabarrena-Aristorena, A;Toska, E
FRONTIERS IN ONCOLOGY
2022-06-14
High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML
Aldaz, P;Martin-Martin, N;Saenz-Antonanzas, A;Carrasco-Garcia, E;Alvarez-Satta, M;Elua-Pinin, A;Pollard, SM;Lawrie, CH;Moreno-Valladares, M;Sampron, N;Hench, J;Lovell-Badge, R;Carracedo, A;Matheu, ...
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2022-05-01
Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen
Rodriguez-Agudo, R;Goikoetxea-Usandizaga, N;Serrano-Macia, M;Fernandez-Tussy, P;Fernandez-Ramos, D;Lachiondo-Ortega, S;Gonzalez-Recio, I;Gil-Pitarch, C;Mercado-Gomez, M;Moran, L;Bizkarguenaga, ...
ANTIOXIDANTS
2022-05-01
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Araujo, AM;Abaurrea, A;Azcoaga, P;Lopez-Velazco, JI;Manzano, S;Rodriguez, J;Rezola, R;Egia-Mendikute, L;Valdes-Mora, F;Flores, JM;Jenkins, L;Pulido, L;Osorio-Querejeta, I;Fernandez-Nogueira, ...
JOURNAL OF CLINICAL INVESTIGATION
2022-04-01
Angiocrine polyamine production regulates adiposity
Monelli, E;Villacampa, P;Zabala-Letona, A;Martinez-Romero, A;Llena, J;Beiroa, D;Gouveia, L;Chivite, I;Zagmutt, S;Gama-Perez, P;Osorio-Conles, O;Muixi, L;Martinez-Gonzalez, A;Castillo, SD;Martin-Martin, ...
NATURE METABOLISM
2022-03-14
PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer
Zabala-Letona, A;Arruabarrena-Aristorena, A;Fernandez-Ruiz, S;Viera, C;Carlevaris, O;Ercilla, A;Mendizabal, I;Martin, T;Macchia, A;Camacho, L;Pujana-Vaquerizo, M;Sanchez-Mosquera, P;Torrano, ...
ONCOGENESIS
2022-02-23
Prospects of Surface-Enhanced Raman Spectroscopy for Biomarker Monitoring toward Precision Medicine
Plou, J;Valera, PS;Garcia, I;de Albuquerque, CDL;Carracedo, A;Liz-Marzan, LM
ACS PHOTONICS
2022-02-16